InsidersTradesSigma
Follow the Aurinia Pharmaceuticals Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Aurinia Pharmaceuticals Inc. has logged 172 public disclosures. Market capitalisation: €2.2bn. The latest transaction was filed on 25 August 2026 (57 - Exercise of rights). Among the most active insiders: Tang, Kevin. The full history is accessible without an account.
172
Insider Decl.
n/a
Thresholds
€32m
23 ops.
Buy Volume
€7m
35 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Aurinia Pharmaceuticals Inc. Strong Buy (bullish), based on 7 analysts. Average price target: US$17.86.
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 1,661 of 29,063 companies
78.1
score / 100
Value66
Quality90
FCF yld6.3%
Earn yld13%
EV/EBITDA16.1x
ROE66%
Gross mgn88%
Net mgn·
Debt/EBITDA0.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 25 August 2026
Declarations172 total
42,052 shares@ CA$16.97Rights Performance AwardTSXSEDI:4768792
21,077 shares@ CA$16.97Common SharesTSXSEDI:4768789
360 sharesCommon SharesTSXSEDI:4768784
Canonical exit: 19 Nov 2026 (T+90)
20,975 shares@ US$16.970.016% mcap25.6% of flowCommon StockSEC:0001837798-26-000013:0
47,000 shares@ US$15.300.032% mcap100.0% of flowCommonSEC144:0001837798-26-000010
OptionsTSXSEDI:4734885
OptionsTSXSEDI:4734884
Common SharesTSXSEDI:4734882
Common SharesTSXSEDI:4734881
Common SharesTSXSEDI:4734879
Common SharesTSXSEDI:4734876
23,931 shares@ CA$15.670.011% mcap100.0% of flowOptionsTSXSEDI:4731982
23,931 shares@ CA$15.670.011% mcap100.0% of flowOptionsTSXSEDI:4731981
23,931 shares@ CA$15.670.011% mcap100.0% of flowOptionsTSXSEDI:4731973
23,931 shares@ CA$15.670.011% mcap100.0% of flowOptionsTSXSEDI:4731965
9,593 shares@ US$16.52140.0077% mcap100.0% of flowCommonSEC144:0001950047-26-005702
25,000 shares@ US$16.33740.020% mcap0.7% of flowCommonSEC144:0001950047-26-005622
5,000 shares@ CA$1.650.0002% mcap0.1% of flowOptionsTSXSEDI:4728385
Canonical exit: 31 Aug 2026 (T+90)
OptionsTSXSEDI:4728383
5,000 shares@ CA$1.650.0002% mcap0.1% of flowOptionsTSXSEDI:4728381
Canonical exit: 31 Aug 2026 (T+90)
OptionsTSXSEDI:4728241
103,002 shares@ CA$15.280.046% mcap12.6% of flowCommon SharesTSXSEDI:4728152
Canonical exit: 31 Aug 2026 (T+90)
49 shares@ CA$15.340.0000% mcap0.0% of flowCommon SharesTSXSEDI:4728150
Canonical exit: 30 Aug 2026 (T+90)
171,760 shares@ CA$15.280.077% mcap21.1% of flowCommon SharesTSXSEDI:4728147
Canonical exit: 30 Aug 2026 (T+90)
Common SharesTSXSEDI:4728145
25 of 172 declarations
关于 Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc.（股票代码：AUPH）是一家在美国纳斯达克上市的美国生物制药公司。从国际股权角度来看，Aurinia 最好被理解为一家专注于专业制药业务而非广泛的药物开发商：其核心理念围绕着自身免疫和肾脏疾病，这些疾病存在显著的未满足医疗需求。该公司具有加拿大历史渊源，但其当前的商业身份立足于美国市场及其主要资产 voclosporin 的生命周期管理。 Aurinia 的主要商业产品是 LUPKYNIS® (voclosporin)，该公司称其为首个获得 FDA 批准的用于治疗活动性狼疮性肾炎成年患者的口服疗法。该批准标志着公司从开发阶段的生物技术公司向具有产品收入的商业阶段生物制药公司的决定性转变。因此，该公司的商业模式高度集中：它专注于为目标患者群体开发、商业化和扩大治疗方案的可及性，特别是在自身免疫和肾脏疾病领域。 在竞争方面，Aurinia 在一个专业且临床要求高的市场中运营。狼疮性肾炎是一种严重且难以治疗的疾病，这意味着市场份额不仅取决于疗效和安全性，还取决于医生的采纳、报销的可及性以及公司的商业执行能力。Aurinia 的差异化在于其口服疗法特性、监管定位以及在治疗选择有限的利基适应症中控制品牌产品。如果采纳持续，这种集中可能是一种优势，但它也带来了产品特有的风险。 从地理上看，Aurinia 主要集中在北美业务，美国是主要的商业和监管平台。该公司还通过国际监管和合作途径寻求将 voclosporin 的覆盖范围扩展到美国以外，这反映了在多个市场创造价值的更广泛愿望。从历史上看，该业务可追溯到成立于 1993 年的 Isotechnika Pharma Inc.，这使得 Aurinia 在 LUPKYNIS 最终推出之前拥有悠久的开发历史。 公司最新披露的信息显示 LUPKYNIS 的商业势头持续强劲，在最新报告期内实现了同比收入增长。对于投资者而言，这是一个重要的信号：Aurinia 的故事越来越关乎执行、市场渗透以及维持已获批疗法的商业价值，而非二元化的临床阶段结果。简而言之，Aurinia 是一家在纳斯达克上市的美国生物制药公司，在狼疮性肾炎和自身免疫疾病治疗领域拥有集中但具有战略重要性的利基市场。
